PTC THERAPEUTICS, INC.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name(Title) | Action Taken(Date of Action) | Type of TradingArrangement | Nature of TradingArrangement | Duration of TradingArrangement | Aggregate Numberof Securities |
|---|---|---|---|---|---|
| Christine Utter (Chief Accounting Officer and Head of People Services) | Adoption (September 16, 2025) | Rule 10b5-1 trading arrangement | Sale | Until September 15, 2026, or until such earlier date upon which all transactions are completed | Up to 57,654 shares |
| Eric Pauwels (Chief Business Officer) | Amendment (September 16, 2025) | Rule 10b5-1 trading arrangement | Sale | Until June 3, 2026, or until such earlier date upon which all transactions are completed | Up to 72,700 shares |
| Mark Boulding (Chief Legal Officer) | Adoption (September 10, 2025) | Rule 10b5-1 trading arrangement | Sale | Until March 5, 2027, or until such earlier date upon which all transactions are completed | Up to 259,346 shares* |
| Glenn D. Steele Jr. (Director) | Adoption (September 8, 2025) | Rule 10b5-1 trading arrangement | Sale | Until January 5, 2026, or until such earlier date upon which all transactions are completed | Up to 12,000 shares |
| * | This Rule 10b5-1 trading arrangement includes up to 86,812 shares of Company common stock available to be sold under Mr. Boulding’s previously executed Rule 10b5-1 trading arrangement, or the Prior Plan, which expires on March 3, 2026. Such shares are only available to be sold under this trading arrangement to the extent they remain unsold under the Prior Plan upon its expiration or termination. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.